Compound index

Incretin & Metabolic Receptor Agonists

Tirzepatide

Also known as Mounjaro · Zepbound

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Overview

A dual GIP/GLP-1 receptor agonist in specific FDA-approved medicines.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Mounjaro · Type 2 Diabetes

    Glycemic control in adults and children aged 10 and older with type 2 diabetes, with diet and physical activity.

    Authoritative label record
  • Zepbound · Weight Management

    Long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition.

    Authoritative label record
  • Zepbound · Sleep Apnea

    Moderate-to-severe obstructive sleep apnea in adults with obesity.

    Authoritative label record
  • Mounjaro · Cardiovascular Risk

    Reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Evidence at a glance

Large randomized trials support product-specific indications; population and formulation boundaries matter.

Key sources

Targeted current-label and chronology check: November 19, 2026. Initial adult approval and later pediatric/cardiovascular expansions are distinct; trial summaries are not an exhaustive systematic review.

Related compounds

  • Retatrutide

    Same scientific class · A 39-amino-acid chain. · Late-stage human trials

  • Semaglutide

    Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications

Related glossary terms